Sarah Hibbitts

Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes.

V. Engelhard, C. Slingluff, W. Grosh, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.

V. Engelhard, C. Slingluff, W. Grosh, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunologic and Clinical Outcomes of a Randomized Phase II Trial of Two Multipeptide Vaccines for Melanoma in the Adjuvant Setting

C. Slingluff, W. Grosh, G. Petroni, 2007, Clinical Cancer Research.

Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule.

E. Bissonette, C. Slingluff, W. Grosh, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of the Sentinel Immunized Node for Immune Monitoring of Cancer Vaccines

E. Bissonette, C. Slingluff, W. Grosh, 2008, Annals of Surgical Oncology.

MAGE-A1-, MAGE-A10-, and gp100-Derived Peptides Are Immunogenic When Combined with Granulocyte-Macrophage Colony-Stimulating Factor and Montanide ISA-51 Adjuvant and Administered as Part of a Multipeptide Vaccine for Melanoma1

Gina R Petroni, E. Bissonette, C. Slingluff, 2005, The Journal of Immunology.